NCT05225077
Unknown
Phase 4
Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease
InterventionsDapagliflozin 10 MG [Farxiga]
Overview
- Phase
- Phase 4
- Intervention
- Dapagliflozin 10 MG [Farxiga]
- Conditions
- Renal Insufficiency, Chronic
- Sponsor
- Dong-A University
- Enrollment
- 600
- Locations
- 1
- Primary Endpoint
- Incidence of contrast induced nephropathy
- Last Updated
- 4 years ago
Overview
Brief Summary
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.
Investigators
Moo Hyun Kim
Professor
Dong-A University
Eligibility Criteria
Inclusion Criteria
- •Age\>18 years
- •Written informed consent
- •Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 \[CKD stage G1-G3\]
- •Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients
Exclusion Criteria
- •Active malignancy
- •Class I or equivalent indication for treatment with a SGLT2 inhibitor
- •Pregnancy or willing of pregnancy during the follow up period
- •Active urogenital infection
- •Diabetes mellitus type 1
- •History of diabetic ketoacidosis
- •Cardiogenic shock
- •eGFR \< 29 ml/min/1.73m2
Arms & Interventions
Dapagliflozin 10mg group
Dapagliflozin 10 mg once a day for 1 month after the procedure.
Intervention: Dapagliflozin 10 MG [Farxiga]
Outcomes
Primary Outcomes
Incidence of contrast induced nephropathy
Time Frame: 48 hours
Serum creatinine (Scr) elevation of \>25% or \>0.5 mg/dl (44 μmol/l) from baseline within 48 hours
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney DiseaseChronic Kidney DiseaseNCT03036150AstraZeneca4,304
Recruiting
Not Applicable
Effect of Dapagriflozin on renal dysfunction in patients with heart failurechronic heart failureJPRN-UMIN000044902Mitsui Memorial Hospital100
Recruiting
Not Applicable
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis PatientsPeritoneal Dialysis ComplicationRenal Function AggravatedSodium-glucose Co-transporter-2 InhibitorsNCT06398977Sichuan Academy of Medical Sciences70
Completed
Not Applicable
Effects of dapagliflozin on renal function in patients with type 2 diabetes [Diamond study-4]patients with type 2 diabetesJPRN-UMIN000020185Diamond study group15
Completed
Phase 2
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT00976495AstraZeneca154